0001181431-13-051156.txt : 20130930
0001181431-13-051156.hdr.sgml : 20130930
20130930200032
ACCESSION NUMBER: 0001181431-13-051156
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130926
FILED AS OF DATE: 20130930
DATE AS OF CHANGE: 20130930
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO BIOSCIENCES INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ANDO DALE G
CENTRAL INDEX KEY: 0001202278
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 131124817
MAIL ADDRESS:
STREET 1: C/O CELL GENESYS INC
STREET 2: 500 FORBES BLVD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
rrd391605.xml
FORM 4
X0306
4
2013-09-26
0
0001001233
SANGAMO BIOSCIENCES INC
SGMO
0001202278
ANDO DALE G
C/O SANGAMO BIOSCIENCES INC.
POINT RICHMOND TECH CNTR, 501 CANAL BLVD
RICHMOND
CA
94804
0
1
0
0
VP, Therapeutic Dev. & CMO
Common Stock
2013-09-26
4
M
0
10000
3.61
A
94798
D
Common Stock
2013-09-26
4
M
0
2000
3.45
A
96798
D
Common Stock
2013-09-26
4
S
0
12000
10.5742
D
84798
D
Common Stock
2013-09-26
4
M
0
3000
5.19
A
87798
D
Common Stock
2013-09-26
4
S
0
3000
10.5613
D
84798
D
Employee Stock Option (Right to Buy)
3.61
2013-09-26
4
M
0
10000
0.00
D
2014-08-01
Common Stock
10000
20000
D
Employee Stock Option (Right to Buy)
3.45
2013-09-26
4
M
0
2000
0.00
D
2018-12-09
Common Stock
2000
196000
D
Employee Stock Option (Right to Buy)
5.19
2013-09-26
4
M
0
3000
0.00
D
2014-12-19
Common Stock
3000
18000
D
The sales reported in this Form 4 were effected pursuant to the Rule 10b5-1 trading plan adopted by the Reporting Person on June 25, 2013.
Includes 50,000 shares and 35,000 shares subject to restricted stock units granted on December 8, 2011 and December 6, 2012, respectively, which will be issued as such units vest in accordance with their terms.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.45 to $10.62, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.45 to $10.62, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
All shares underlying this option are vested and immediately exercisable.
/s/ Florence Tam, attorney-in-fact
2013-09-30